Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)
Fundamental measurement is the basis for a rational assessment of patient reported outcome (PRO) value claims; both as response to therapy and the submission of credible and evaluable value claims to formulary committees and other health system decision makers. It is important to emphasize the impo...
Main Author: | Paul C Langley |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2022-08-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/4861 |
Similar Items
-
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
by: Dong T, et al.
Published: (2023-04-01) -
Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials
by: Mehrdad Rabiee Rad, et al.
Published: (2023-01-01) -
Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis
by: Hussain Sohail Rangwala, et al.
Published: (2023-12-01) -
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
by: Smita Scholtz, et al.
Published: (2023-10-01) -
Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
by: Areeba Memon, et al.
Published: (2023-12-01)